About Sidero Bioscience

Sidero Mission Statement


Sidero was founded with a transformative spirit and lofty objective.

The World Health Organization states that Iron Deficiency is the most common and widespread nutritional disorder in the world.


The Sidero mission is to provide a safe, effective, and economical remedy for iron deficiency for all peoples of the world. 

Sidero is based on intellectual property developed at The Pennsylvania State University’s Hershey Medical Center in Hershey, Pennsylvania.  Sidero is developing novel biotherapeutics to treat gastrointestinal system disorders with significant unmet medical need.  Sidero is initially targeting the high-value Iron Deficiency market, providing one of the fastest growing investment returns in medical research.  The patented Siderosorb™ platform advances therapeutic protein/complex delivery directly to the intestine by oral ingestion in a pill, liquid, sachet or other ingestion formats.  The Iron Deficiency indication is currently a vastly under-served market with substantial unmet medical need. 


Sidero Facilities


In addition to small research laboratory and office space located in the Hershey Center for Applied Research (HCAR, http://www.hersheyresearch.com/) Sidero utilizes laboratory space of long term collaborators at The Pennsylvania State University and the University of Wisconsin that are fully equipped for performing the mammalian cell culture, molecular biology, biochemistry and animal models required for our product development.  Sidero has established strong relationships with external Contract Research Organizations (CRO), Contract Manufacturing Organizations (CMO), Key Opinion Leaders (KOLs), regulatory support, and the Food and Drug Administration (FDA) to provide a solid pathway to advance BioFe™ to the market. 


The Iron Deficiency Market


Sidero targets the most common and widespread nutritional disorder in the world, Iron Deficiency (ID).  Iron deficiency leads to iron deficiency anemia (IDA), impedes motor and mental development in children leading to lifelong cognitive deficiencies and causes fatigue, reduced work capacity, and reduced quality of life in adults.  Current approaches to the treatment of iron deficiency are plainly inadequate.  Oral iron supplementation is inexpensive, however, it is ineffective in ~30% of patients and also suffers from substantial GI side effects, reducing compliance by up to 50%.  While intravenous iron replacement therapies are generally safe and effective, they are expensive (>$2000/month) and invasive to deliver leading to both payor and patient dissatisfaction. 

The IV-Iron therapeutic market is growing rapidly and is expected to reach $1.8 Billion by 2020. 

Sidero Value Based Care


As cost pressures continue to build for healthcare, successful medical products require a blend of innovation for patients and value for the insurance company.  Sidero’s BioFe™ aims to provide medical relief to ID and IDA patients and financial relief to payors.  Our Value Based Care attributes include:


  • Sidero uses cutting-edge, patented medical technology.
  • A clear market between inexpensive but inefficient oral iron supplements and effective but expensive/onerous IV-iron therapies exists, which is the target for BioFe™.
  • Iron deficiency is the most common nutritional disorder worldwide with a current market of ~$2 Billion/yr.
  • Decades of scientific research support the development of BioFe™.
  • Nutritional yeast has been used for 9,000 years to make foods and ferment beverages.
  • Ferritin/iron is the natural biologic complex in breast milk providing safe and effective dietary iron as nature intended.